

Special Issue

Virulence and Antimicrobial Resistance: Convergence or Divergence

Message from the Guest Editors

Antimicrobial resistance and virulence are among the most important properties of bacteria in practice, but traditionally they were considered by microbiologists as relatively independent phenomena. Even the results of research in these areas have been published in various journals. The situation changed dramatically after the appearance of genetic lines of *Klebsiella* possessing both the properties of multiple resistance and increased virulence. The number of works on the problem is growing exponentially; a number of convergence mechanisms have already been described, but progress in the development of treatment methods is very small.

Obviously, to solve this problem, a deeper understanding of evolution and the molecular mechanisms of convergence is required, which in turn requires fundamental research involving systems biology methods. Although the phenomenon of convergence has been found in *Klebsiella*, it is likely that its formation and distribution is not limited to this species. This Special Issue of the multidisciplinary journal *Biomedicines* provides a unique platform for researchers from various fields to join forces to curb convergence and virulence.

Guest Editors

Dr. Sergey Sidorenko

Pediatric Research and Clinical Center for Infectious Diseases, Saint Petersburg, Russia

Dr. Vladimir Ageevets

Pediatric Research and Clinical Center for Infectious Diseases, Saint Petersburg, Russia

Deadline for manuscript submissions

closed (31 August 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/130222

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).